{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:51:54Z","timestamp":1777517514507,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2020YFC2008306"],"award-info":[{"award-number":["2020YFC2008306"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-023-05092-z","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T06:01:51Z","timestamp":1690351311000},"page":"4509-4521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy"],"prefix":"10.1007","volume":"182","author":[{"given":"Xingmeng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifeng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"issue":"13","key":"5092_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","volume":"327","author":"AM Kanner","year":"2022","unstructured":"Kanner AM, Bicchi MM (2022) Antiseizure Medications for Adults With Epilepsy: A Review. JAMA 327(13):1269\u20131281","journal-title":"JAMA"},{"issue":"3","key":"5092_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12074","volume":"54","author":"T Glauser","year":"2013","unstructured":"Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, K\u00e4lvi\u00e4inen R et al (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54(3):551\u2013563","journal-title":"Epilepsia"},{"issue":"8","key":"5092_CR3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1592\/phco.21.11.904.34513","volume":"21","author":"TA Glauser","year":"2001","unstructured":"Glauser TA (2001) Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 21(8):904\u2013919","journal-title":"Pharmacotherapy"},{"issue":"10","key":"5092_CR4","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/aps.2014.76","volume":"35","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhang HN, Niu CH, Gao P, Chen YJ, Peng J et al (2014) Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin 35(10):1342\u20131350","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"5092_CR5","first-page":"1239","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI et al (2008) Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies Epilepsia 49(7):1239\u20131276","journal-title":"ILAE Commission on Therapeutic Strategies Epilepsia"},{"issue":"7","key":"5092_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/17512433.2021.1917377","volume":"14","author":"YT Chen","year":"2021","unstructured":"Chen YT, Wang CY, Yin YW, Li ZR, Lin WW, Zhu M et al (2021) Population pharmacokinetics of oxcarbazepine: a systematic review. Expert Rev Clin Pharmacol 14(7):853\u2013864","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"5092_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","volume":"42","author":"TW May","year":"2003","unstructured":"May TW, Korn-Merker E, Rambeck B (2003) Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 42(12):1023\u20131042","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"5092_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/jcpt.12792","volume":"44","author":"CY Chen","year":"2019","unstructured":"Chen CY, Zhou Y, Cui YM, Yang T, Zhao X, Wu Y (2019) Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin Pharm Ther 44(2):300\u2013311","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"5092_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/WNF.0b013e31824150a5","volume":"35","author":"KJ Park","year":"2012","unstructured":"Park KJ, Kim JR, Joo EY, Seo DW, Hong SB, Ko JW et al (2012) Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. Clin Neuropharmacol 35(1):40\u201344","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"5092_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.dmpk.2014.12.002","volume":"30","author":"I Sugiyama","year":"2015","unstructured":"Sugiyama I, Bouillon T, Yamaguchi M, Suzuki H, Hirota T, Fink M (2015) Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities. Drug Metab Pharmacokinet 30(2):160\u2013167","journal-title":"Drug Metab Pharmacokinet"},{"issue":"12","key":"5092_CR11","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1111\/bcp.13392","volume":"83","author":"C Rodrigues","year":"2017","unstructured":"Rodrigues C, Chiron C, Rey E, Dulac O, Comets E, Pons G et al (2017) Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. Br J Clin Pharmacol 83(12):2695\u20132708","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"5092_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.pediatrneurol.2005.05.011","volume":"33","author":"RS Northam","year":"2005","unstructured":"Northam RS, Hernandez AW, Litzinger MJ, Minecan DN, Glauser TA, Mangat S et al (2005) Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol 33(5):337\u2013344","journal-title":"Pediatr Neurol"},{"key":"5092_CR13","doi-asserted-by":"crossref","unstructured":"Antunes NJ, van Dijkman SC, Lanchote VL, Wichert-Ana L, Coelho EB, Alexandre Junior V et al (2017) Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. Eur J Pharm Sci 109s:S116\u2013s123","DOI":"10.1016\/j.ejps.2017.05.034"},{"issue":"3","key":"5092_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00228-018-2600-8","volume":"75","author":"WW Lin","year":"2019","unstructured":"Lin WW, Li XW, Jiao Z, Zhang J, Rao X, Zeng DY et al (2019) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. Eur J Clin Pharmacol 75(3):381\u2013392","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"5092_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/FTD.0000000000000644","volume":"41","author":"WW Lin","year":"2019","unstructured":"Lin WW, Wang CL, Jiao Z, Yu XL, Zhang J, Zhang WB et al (2019) Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis. Ther Drug Monit 41(5):665\u2013673","journal-title":"Ther Drug Monit"},{"issue":"8","key":"5092_CR16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.5414\/CP202078","volume":"52","author":"J Peng","year":"2014","unstructured":"Peng J, Zhang HN, Liu ZS, Xu H, Wang Y (2014) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. Int J Clin Pharmacol Ther 52(8):684\u2013692","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"5092_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s13318-015-0266-5","volume":"41","author":"Y Yu","year":"2016","unstructured":"Yu Y, Zhang Q, Xu W, Lv C, Hao G (2016) Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. Eur J Drug Metab Pharmacokinet 41(4):345\u2013351","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"5092_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yebeh.2013.07.016","volume":"29","author":"I Wegner","year":"2013","unstructured":"Wegner I, Wilhelm AJ, Sander JW, Lindhout D (2013) The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav 29(1):217\u2013221","journal-title":"Epilepsy Behav"},{"issue":"2","key":"5092_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/01.ftd.0000155342.93489.fd","volume":"27","author":"JA Armijo","year":"2005","unstructured":"Armijo JA, Vega-Gil N, Shushtarian M, Ad\u00edn J, Herranz JL (2005) 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit 27(2):199\u2013204","journal-title":"Ther Drug Monit"},{"issue":"12","key":"5092_CR20","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamaneurol.2022.3651","volume":"79","author":"D McKnight","year":"2022","unstructured":"McKnight D, Morales A, Hatchell KE, Bristow SL, Bonkowsky JL, Perry MS et al (2022) Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice. JAMA Neurol 79(12):1267\u20131276","journal-title":"JAMA Neurol"},{"issue":"4","key":"5092_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/pgs.14.186","volume":"16","author":"CL Ma","year":"2015","unstructured":"Ma CL, Wu XY, Jiao Z, Hong Z, Wu ZY, Zhong MK (2015) SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy. Pharmacogenomics 16(4):347\u2013360","journal-title":"Pharmacogenomics"},{"key":"5092_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.seizure.2017.07.015","volume":"51","author":"C Shen","year":"2017","unstructured":"Shen C, Zhang B, Liu Z, Tang Y, Zhang Y, Wang S et al (2017) Effects of ABCB1, ABCC2, UGT2B7 and HNF4\u03b1 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy. Seizure 51:102\u2013106","journal-title":"Seizure"},{"issue":"12","key":"5092_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014908","volume":"98","author":"X Yang","year":"2019","unstructured":"Yang X, Yan Y, Fang S, Zeng S, Ma H, Qian L et al (2019) Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms. Medicine (Baltimore) 98(12):e14908","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"5092_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00228-016-2157-3","volume":"73","author":"Y Lu","year":"2017","unstructured":"Lu Y, Fang Y, Wu X, Ma C, Wang Y, Xu L (2017) Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. Eur J Clin Pharmacol 73(3):307\u2013315","journal-title":"Eur J Clin Pharmacol"},{"issue":"e1","key":"5092_CR25","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1136\/ejhpharm-2022-003357","volume":"30","author":"Q Yang","year":"2023","unstructured":"Yang Q, Hu Y, Zhang X, Zhang X, Dai H, Li X (2023) Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients. Eur J Hosp Pharm 30(e1):e90\u2013e96","journal-title":"Eur J Hosp Pharm"},{"issue":"12","key":"5092_CR26","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/bmc.3789","volume":"30","author":"J Dupouey","year":"2016","unstructured":"Dupouey J, Doudka N, Belo S, Blin O, Guilhaumou R (2016) Simultaneous determination of four antiepileptic drugs in human plasma samples using an ultra-high-performance liquid chromatography tandem mass spectrometry method and its application in therapeutic drug monitoring. Biomed Chromatogr 30(12):2053\u20132060","journal-title":"Biomed Chromatogr"},{"issue":"5","key":"5092_CR27","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1111\/j.1528-1167.2011.03097.x","volume":"52","author":"I Manna","year":"2011","unstructured":"Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U et al (2011) A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52(5):e40-44","journal-title":"Epilepsia"},{"issue":"10","key":"5092_CR28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/FPC.0b013e3283498131","volume":"21","author":"M Ufer","year":"2011","unstructured":"Ufer M, von St\u00fclpnagel C, Muhle H, Haenisch S, Remmler C, Majed A et al (2011) Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics 21(10):624\u2013630","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"5092_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.18433\/J37S4K","volume":"18","author":"P Wang","year":"2015","unstructured":"Wang P, Yin T, Ma HY, Liu DQ, Sheng YA, Zhou BT (2015) First Analysis of the Association Between CYP3A4\/5, ABCB1 Genetic Polymorphisms and Oxcarbazepine Metabolism and Transport in Chinese Epileptic Patients with Oxcarbazepine Monotherapy and Bitherapy. J Pharm Pharm Sci 18(3):256\u2013265","journal-title":"J Pharm Pharm Sci"},{"issue":"3","key":"5092_CR30","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1080\/21655979.2022.2036916","volume":"13","author":"W Zhao","year":"2022","unstructured":"Zhao W, Meng H (2022) Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population. Bioengineered 13(3):7709\u20137745","journal-title":"Bioengineered"},{"issue":"8","key":"5092_CR31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00228-018-2440-6","volume":"74","author":"S Mei","year":"2018","unstructured":"Mei S, Feng W, Zhu L, Li X, Yu Y, Yang W et al (2018) Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model. Eur J Clin Pharmacol 74(8):1029\u20131036","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"5092_CR32","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1038\/s41598-021-85920-0","volume":"11","author":"Y Jang","year":"2021","unstructured":"Jang Y, Yoon S, Kim TJ, Lee S, Yu KS, Jang IJ et al (2021) Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. Sci Rep 11(1):6370","journal-title":"Sci Rep"},{"issue":"3","key":"5092_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629\u2013637","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"5092_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90(2):154\u2013166","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"5092_CR35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. Aaps j 11(3):558\u2013569","journal-title":"Aaps j"},{"issue":"6","key":"5092_CR36","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/FTD.0000000000000805","volume":"42","author":"T Zhao","year":"2020","unstructured":"Zhao T, Yu J, Wang TT, Feng J, Zhao WB, Sun L et al (2020) Impact of ABCB1 Polymorphism on Levetiracetam Serum Concentrations in Epileptic Uygur Children in China. Ther Drug Monit 42(6):886\u2013892","journal-title":"Ther Drug Monit"},{"issue":"2","key":"5092_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00194967","volume":"47","author":"MC Rouan","year":"1994","unstructured":"Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P et al (1994) The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 47(2):161\u2013167","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"5092_CR38","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1124\/molpharm.120.000104","volume":"98","author":"PC Nair","year":"2020","unstructured":"Nair PC, Chau N, McKinnon RA, Miners JO (2020) Arginine-259 of UGT2B7 Confers UDP-Sugar Selectivity. Mol Pharmacol 98(6):710\u2013718","journal-title":"Mol Pharmacol"},{"issue":"4","key":"5092_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00228-017-2395-z","volume":"74","author":"P Wang","year":"2018","unstructured":"Wang P, Lin XQ, Cai WK, Xu GL, Zhou MD, Yang M et al (2018) Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Eur J Clin Pharmacol 74(4):433\u2013442","journal-title":"Eur J Clin Pharmacol"},{"key":"5092_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.seizure.2018.04.006","volume":"58","author":"W Feng","year":"2018","unstructured":"Feng W, Mei S, Zhu L, Yu Y, Yang W, Gao B et al (2018) Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures. Seizure 58:96\u2013100","journal-title":"Seizure"},{"key":"5092_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107554","volume":"213","author":"E Gil-Martins","year":"2020","unstructured":"Gil-Martins E, Barbosa DJ, Silva V, Remi\u00e3o F, Silva R (2020) Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. Pharmacol Ther 213:107554","journal-title":"Pharmacol Ther"},{"issue":"1","key":"5092_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yebeh.2011.02.015","volume":"21","author":"H Meng","year":"2011","unstructured":"Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y (2011) Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav 21(1):27\u201330","journal-title":"Epilepsy Behav"},{"issue":"5","key":"5092_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064827","volume":"8","author":"S Subenthiran","year":"2013","unstructured":"Subenthiran S, Abdullah NR, Joseph JP, Muniandy PK, Mok BT, Kee CC et al (2013) Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital. PLoS ONE 8(5):e64827","journal-title":"PLoS ONE"},{"issue":"5","key":"5092_CR44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","volume":"34","author":"M Lovri\u0107","year":"2012","unstructured":"Lovri\u0107 M, Bo\u017eina N, Hajn\u0161ek S, Kuzman MR, Spori\u0161 D, Lali\u0107 Z et al (2012) Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Ther Drug Monit 34(5):518\u2013525","journal-title":"Ther Drug Monit"},{"issue":"3","key":"5092_CR45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/jcpt.12263","volume":"40","author":"T Keangpraphun","year":"2015","unstructured":"Keangpraphun T, Towanabut S, Chinvarun Y, Kijsanayotin P (2015) Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy. J Clin Pharm Ther 40(3):315\u2013319","journal-title":"J Clin Pharm Ther"},{"key":"5092_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106785","volume":"177","author":"YX Fan","year":"2021","unstructured":"Fan YX, Zhang Z, Meng JR, Yin SJ, Wang P, Zhou T et al (2021) Association of ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A meta-analysis. Epilepsy Res 177:106785","journal-title":"Epilepsy Res"},{"issue":"5811","key":"5092_CR47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.1135308","volume":"315","author":"C Kimchi-Sarfaty","year":"2007","unstructured":"Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al (2007) A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811):525\u2013528","journal-title":"Science"},{"key":"5092_CR48","doi-asserted-by":"publisher","first-page":"1343650","DOI":"10.1155\/2019\/1343650","volume":"2019","author":"M Chouchi","year":"2019","unstructured":"Chouchi M, Klaa H, Ben-Youssef Turki I, Hila L (2019) ABCB1 Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population. Dis Markers 2019:1343650","journal-title":"Dis Markers"},{"issue":"4","key":"5092_CR49","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/14622416.7.4.551","volume":"7","author":"T Seo","year":"2006","unstructured":"Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K et al (2006) ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7(4):551\u2013561","journal-title":"Pharmacogenomics"},{"issue":"1","key":"5092_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11033-013-2866-y","volume":"41","author":"M Seven","year":"2014","unstructured":"Seven M, Batar B, Unal S, Yesil G, Yuksel A, Guven M (2014) The drug-transporter gene MDR1 C3435T and G2677T\/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children. Mol Biol Rep 41(1):331\u2013336","journal-title":"Mol Biol Rep"},{"issue":"5","key":"5092_CR51","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.seizure.2006.02.015","volume":"15","author":"DW Kim","year":"2006","unstructured":"Kim DW, Kim M, Lee SK, Kang R, Lee SY (2006) Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 15(5):344\u2013347","journal-title":"Seizure"},{"issue":"5","key":"5092_CR52","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1528-1167.2005.46304.x","volume":"46","author":"GJ Sills","year":"2005","unstructured":"Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA et al (2005) Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46(5):643\u2013647","journal-title":"Epilepsia"},{"issue":"3","key":"5092_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122043","volume":"10","author":"H Li","year":"2015","unstructured":"Li H, Wang B, Chang C, Wu M, Xu Y, Jiang Y (2015) The roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studies. PLoS ONE 10(3):e0122043","journal-title":"PLoS ONE"},{"key":"5092_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.591828","volume":"11","author":"M Li","year":"2020","unstructured":"Li M, Zhong R, Lu Y, Zhao Q, Li G, Lin W (2020) Association Between SCN1A rs2298771, SCN1A rs10188577, SCN2A rs17183814, and SCN2A rs2304016 Polymorphisms and Responsiveness to Antiepileptic Drugs: A Meta-Analysis. Front Neurol 11:591828","journal-title":"Front Neurol"},{"issue":"5","key":"5092_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233978","volume":"15","author":"EF Baulin","year":"2020","unstructured":"Baulin EF, Kulakovskiy IV, Roytberg MA, Astakhova TV (2020) Brain-related genes are specifically enriched with long phase 1 introns. PLoS ONE 15(5):e0233978","journal-title":"PLoS ONE"},{"issue":"5","key":"5092_CR56","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00228-019-02633-0","volume":"75","author":"L Shi","year":"2019","unstructured":"Shi L, Zhu M, Li H, Wen Z, Chen X, Luo J et al (2019) SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients. Eur J Clin Pharmacol 75(5):655\u2013663","journal-title":"Eur J Clin Pharmacol"},{"key":"5092_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106485","volume":"168","author":"M Liu","year":"2020","unstructured":"Liu M, Mao J, Xu H, Wang J, Zhao P, Xu Q et al (2020) Effects of SCN1A and SCN2A polymorphisms on responsiveness to valproic acid monotherapy in epileptic children. Epilepsy Res 168:106485","journal-title":"Epilepsy Res"},{"issue":"11","key":"5092_CR58","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/FPC.0b013e3283117d67","volume":"18","author":"P Kwan","year":"2008","unstructured":"Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW et al (2008) Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 18(11):989\u2013998","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"5092_CR59","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1007\/s10072-021-05242-x","volume":"42","author":"R Yang","year":"2021","unstructured":"Yang R, Qian R, Chen K, Yi W, Sima X (2021) Genetic polymorphisms in SCN2A are not associated with epilepsy risk and AEDs response: evidence from a meta-analysis. Neurol Sci 42(7):2705\u20132711","journal-title":"Neurol Sci"},{"issue":"10","key":"5092_CR60","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2217\/pgs.13.104","volume":"14","author":"BS Haerian","year":"2013","unstructured":"Haerian BS, Baum L, Kwan P, Tan HJ, Raymond AA, Mohamed Z (2013) SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics 14(10):1153\u20131166","journal-title":"Pharmacogenomics"},{"key":"5092_CR61","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.seizure.2014.09.014","volume":"25","author":"F Che","year":"2015","unstructured":"Che F, Fu Q, Li X, Gao N, Qi F, Sun Z et al (2015) Association of insulin receptor H1085H C>T, insulin receptor substrate 1 G972R and insulin receptor substrate 2 1057G\/A polymorphisms with refractory temporal lobe epilepsy in Han Chinese. Seizure 25:178\u2013180","journal-title":"Seizure"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-023-05092-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T10:08:08Z","timestamp":1697710088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-023-05092-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["5092"],"URL":"https:\/\/doi.org\/10.1007\/s00431-023-05092-z","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"10 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards, and approved by the Ethics Committee of Beijing Children\u2019s Hospital (ID: 2019-k-150).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All of the authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}